欧康维视生物-B(01477.HK)：OT-702获批于中国上市

Core Viewpoint - Oculentis Biotech-B (01477.HK) announced that OT-702 (Aflibercept intravitreal injection, EYLEA® biosimilar) has been approved by the National Medical Products Administration for the treatment of adult neovascular (wet) age-related macular degeneration (nAMD) and diabetic macular edema (DME) [1] Group 1 - OT-702 is developed by the company's partner, Boan Biotech (06955.HK) [1] - The collaboration and exclusive promotion agreement was established in October 2020, under which both parties are to jointly advance the Phase III clinical trial of OT-702 [1] - The company has been granted exclusive rights to promote and commercialize the product in China [1]